» Articles » PMID: 35092404

Intraoperative Molecular Analysis of Total Tumor Load in Sentinel Lymph Node: A Predictor of Axillary Status in Early Breast Cancer

Overview
Specialty Oncology
Date 2022 Jan 29
PMID 35092404
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Axillary lymph node dissection (ALND) remains the standard of care in breast cancer patients with positive sentinel lymph node (SLN). However, approximately 40-60% of patients with positive SLNs have not developed to non-SLN metastasis and ALND seems to be an overtreatment. The purpose of this study was to analyze predictors and define a specific cut-off of total tumor load (TTL) of CK19 that can be used as a predictive factor of non-SLN metastasis in early breast cancer patients.

Materials And Methods: The records of 238 patients with cT1-3N0 breast cancer who had an intraoperative SLN evaluation performed through One-Step nucleic acid (OSNA) assay at Songklanagarind Hospital between 1 January 2015 and 31 December 2019 were examined. Univariate and Multivariate analysis was used to identify clinicopathologic features in SLN-positive patients that predict metastasis to non-SLNs. Finally, receiver operative characteristics (ROC) curves were used to choose an optimal TTL cut-off value.

Results: Of a total of 110 patients who had a positive SLN, only 48 (43.64%) were found to have positive nodes in non-SLN. Multivariate analysis revealed that lymphovascular invasion, type of SLN metastasis and SLN TTL (copies/μL) were independent predictors of positive non-SLNs.  TTL cut-off value was 19,000 copies/μL, with an AUC of 0.838 with 72.7% sensitivity and 84.7% specificity to predict non-SLN metastasis.

Conclusions: The likelihood of positive non-SLNs in patients who showed a positive SLN correlates with lymphovascular invasion, type of SLN metastasis and SLN TTL (copies/μL). Our result revealed that the patients with a SLN TTL ≥19,000 copies/µl continue to attract the recommendation to proceed with ALND. This cut-off value can then help clinicians to assess which patients would benefit from ALND.

Citing Articles

Value of total tumor load as a clinical and pathological factor in the prognosis of breast cancer patients receiving neoadjuvant treatment. Comparison of three populations with three different surgical approaches: NEOVATTL Pro 3 Study.

Martin-Salvago M, Sancho M, Lopez-Garcia M, Cano Jimenez A, Perez-Luque A, Alfaro L Breast Cancer Res Treat. 2023; 200(2):203-215.

PMID: 37219637 PMC: 10241680. DOI: 10.1007/s10549-023-06954-8.

References
1.
Teramoto A, Shimazu K, Naoi Y, Shimomura A, Shimoda M, Kagara N . One-step nucleic acid amplification assay for intraoperative prediction of non-sentinel lymph node metastasis in breast cancer patients with sentinel lymph node metastasis. Breast. 2014; 23(5):579-85. DOI: 10.1016/j.breast.2014.05.026. View

2.
Giuliano A, Hunt K, Ballman K, Beitsch P, Whitworth P, Blumencranz P . Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011; 305(6):569-75. PMC: 5389857. DOI: 10.1001/jama.2011.90. View

3.
Hintzen K, De Rooij L, Schouten N, van Bastelaar J, Corvers S, Janssen A . Molecular analysis of sentinel lymph nodes in patients with breast cancer using one-step nucleic acid amplification (OSNA): Does not lead to overtreatment in the current era of de-escalating axillary management. Surg Oncol. 2020; 35:224-228. DOI: 10.1016/j.suronc.2020.09.010. View

4.
Manzotti M, DellOrto P, Maisonneuve P, Zurrida S, Mazzarol G, Viale G . Reverse transcription-polymerase chain reaction assay for multiple mRNA markers in the detection of breast cancer metastases in sentinel lymph nodes. Int J Cancer. 2001; 95(5):307-12. DOI: 10.1002/1097-0215(20010920)95:5<307::aid-ijc0153>3.0.co;2-q. View

5.
Espinosa-Bravo M, Sansano I, Perez-Hoyos S, Ramos M, Sancho M, Xercavins J . Prediction of non-sentinel lymph node metastasis in early breast cancer by assessing total tumoral load in the sentinel lymph node by molecular assay. Eur J Surg Oncol. 2013; 39(7):766-73. DOI: 10.1016/j.ejso.2013.03.011. View